These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12476093)

  • 1. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin.
    Houle JM; Strong HA
    Retina; 2002 Dec; 22(6):691-7. PubMed ID: 12476093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients.
    Bessler NM;
    Retina; 2004 Aug; 24(4):512-20. PubMed ID: 15300071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
    Azab M; Benchaboune M; Blinder KJ; Bressler NM; Bressler SB; Gragoudas ES; Fish GE; Hao Y; Haynes L; Lim JI; Menchini U; Miller JW; Mones J; Potter MJ; Reaves A; Rosenfeld PJ; Strong A; Su XY; Slakter JS; Schmidt-Erfurth U; Sorenson JA; ;
    Retina; 2004 Feb; 24(1):1-12. PubMed ID: 15076937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on verteporfin in subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs Aging; 2004; 21(3):203-9. PubMed ID: 14979737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
    Verteporfin Roundtable Participants
    Retina; 2005; 25(2):119-34. PubMed ID: 15689800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.
    ; ;
    Retina; 2002 Feb; 22(1):6-18. PubMed ID: 11884872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
    Blumenkranz MS; Bressler NM; Bressler SB; Donati G; Fish GE; Haynes LA; Lewis H; Miller JW; Monés JM; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Schachat AP; Schmidt-Erfurth U; Sickenburg M; Singerman LJ; Slakter JS; Strong A; Vannier S;
    Arch Ophthalmol; 2002 Oct; 120(10):1307-14. PubMed ID: 12365909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM;
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Japanese Age-Related Macular Degeneration Tial (JAT) Study Group
    Am J Ophthalmol; 2003 Dec; 136(6):1049-61. PubMed ID: 14644215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
    Kaiser PK;
    Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications after photodynamic therapy.
    Schnurrbusch UE; Jochmann C; Einbock W; Wolf S
    Arch Ophthalmol; 2005 Oct; 123(10):1347-50. PubMed ID: 16219725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
    Miller JW; Schmidt-Erfurth U; Sickenberg M; Pournaras CJ; Laqua H; Barbazetto I; Zografos L; Piguet B; Donati G; Lane AM; Birngruber R; van den Berg H; Strong A; Manjuris U; Gray T; Fsadni M; Bressler NM; Gragoudas ES
    Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Verteporfin and photosensitivity in diabetic].
    Asensio Sánchez VM; Corral Azor A; García Pascual A
    Arch Soc Esp Oftalmol; 2003 May; 78(5):277-9. PubMed ID: 12789632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].
    Chen YX; Ge J; Yan M; Jin CJ; Zhang MX; Dong FT; Lu F; Zhang CF; Zhao JL
    Zhonghua Yan Ke Za Zhi; 2007 Mar; 43(3):198-205. PubMed ID: 17605900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
    Verteporfin in Photodynamic Therapy Study Group
    Ophthalmology; 2001 May; 108(5):841-52. PubMed ID: 11320011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.
    Blinder KJ; Blumenkranz MS; Bressler NM; Bressler SB; Donato G; Lewis H; Lim JI; Menchini U; Miller JW; Mones JM; Potter MJ; Pournaras C; Reaves A; Rosenfeld P; Schachat AP; Schmidt-Erfurth U; Sickenberg M; Singerman LJ; Slakter JS; Strong HA; Virgili G; Williams GA
    Ophthalmology; 2003 Apr; 110(4):667-73. PubMed ID: 12689884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.